Mikhail Blagosklonny published the findings of a test set to determine if Everolimus, a Rapamycin version, had the potential of slowing the aging process. According to a report on Impact Journals, the drug’s tests indicated a promising future for people looking to increase their life spans by controlling the body’s biological operations.
Mikhail Blagosklonny is a dedicated scientist who studies the intricacies of cancer and aging. He researches on niches such as cell cycle, anticancer therapies, mitosis, tumor suppression, ontogenesis, drug resistance, apoptosis and selective cell protection. Additionally, he couples his time as an editor of Cell Cycle, the American Journal of Pathology, PLOS ONE, International Journal of Cancer, and Oncotarget, and a professor at the Roswell Park Institute. He developed a hypothesis citing that TOR signaling can potentially reduce the aging process and reverse a patient’s cancer inflicted body back to health. He suggested that the use of Rapamycin, a prevalent cancer drug could extend that lives of people.
He has numerous published articles on Impact Journals and Nature, where he speaks on chemotherapy engineering, aging hyperfunctions, and cell cyclo therapeutics. To date, Mikhail has more than 300 published research articles, reviews, and book chapters. He has more than 25,000 citations and h-index 83. Mikhail is an editor in chief of Oncotarget and Cell Cycle and an associate editor at PLOS ONE, International Journal of Cancer, and the American Journal of Pathology. He revealed that he has an innate love for the human race and has the vision to alienate premature deaths by cancer and preventable aging.
Mikhail began his career in the field of oncology at the Roswell Park Cancer Institute in 2009. Before the joining the school, he was deployed as a specialist in the field in other companies and institutions. He received his medicine degree in internal medicine from the First Pavlov State Medical University of Saint Petersburg. He has a doctorate in cardiology and experimental medicine from the same institution. In 2002, Mikhail Blagosklonny joined the New York Medicine College located in Valhalla as an associate professor. He later became a senior scientist working for Ordway Research Institute. During his recruiting into Roswell, the senior vice president of the firm stated that Mikhail was a great asset towards finding cancer treatments and improving therapeutics. He added that the school’s enthusiasm and investment in the field would provide Mikhail with a suitable environment to execute in-depth research. Roswell has a long standing history in developing methodologies that protect healthy cells during cancer therapies such as chemo and radiotherapy. In the years, the firm has had a profound involvement in the selection of the most suitable anti-cancer drugs, tissue-specific therapies, and age reversal by targeting particular cells and organs. Visit ResearchGate.Net to learn more about Mikhail’s latest work.